CYP Stock Overview
Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Cynata Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.21 |
| 52 Week High | AU$0.23 |
| 52 Week Low | AU$0.10 |
| Beta | 0.81 |
| 1 Month Change | 20.00% |
| 3 Month Change | 44.83% |
| 1 Year Change | 23.53% |
| 3 Year Change | -66.13% |
| 5 Year Change | -82.13% |
| Change since IPO | -95.43% |
Recent News & Updates
Recent updates
We're A Little Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Rate
Feb 09
We're Interested To See How Cynata Therapeutics (ASX:CYP) Uses Its Cash Hoard To Grow
Feb 02We Think Cynata Therapeutics (ASX:CYP) Can Easily Afford To Drive Business Growth
Sep 09Here's Why We're Not At All Concerned With Cynata Therapeutics' (ASX:CYP) Cash Burn Situation
May 26Here's Why We're Not Too Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Situation
Dec 31We're Not Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn
Aug 11Shareholder Returns
| CYP | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 2.4% | 1.9% | 0.9% |
| 1Y | 23.5% | -7.7% | 5.6% |
Return vs Industry: CYP exceeded the Australian Biotechs industry which returned -7.7% over the past year.
Return vs Market: CYP exceeded the Australian Market which returned 5.6% over the past year.
Price Volatility
| CYP volatility | |
|---|---|
| CYP Average Weekly Movement | 15.6% |
| Biotechs Industry Average Movement | 11.4% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in AU Market | 17.6% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: CYP's share price has been volatile over the past 3 months.
Volatility Over Time: CYP's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | n/a | Kilian Kelly | www.cynata.com |
Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company’s lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops CYP-004, which is in Phase III clinical trial used for the treatment of osteoarthritis; and CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds.
Cynata Therapeutics Limited Fundamentals Summary
| CYP fundamental statistics | |
|---|---|
| Market cap | AU$37.72m |
| Earnings (TTM) | -AU$13.65m |
| Revenue (TTM) | AU$2.40m |
15.7x
P/S Ratio-2.8x
P/E RatioIs CYP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CYP income statement (TTM) | |
|---|---|
| Revenue | AU$2.40m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$2.40m |
| Other Expenses | AU$16.04m |
| Earnings | -AU$13.65m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.076 |
| Gross Margin | 100.00% |
| Net Profit Margin | -568.80% |
| Debt/Equity Ratio | 0% |
How did CYP perform over the long term?
See historical performance and comparison